viewCanntab Therapeutics Ltd

Canntab Therapeutics spends C$1.3M on cannabis processing equipment in two all-stock deals

The company is offering more than 2.5 million shares in total at a price of C$0.51 per share

$100 bill appearing to grow from a cannabis plant
Canntab is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations

Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) has reached a pair of binding agreements to buy $1.3 million worth of cannabis processing equipment and leasehold improvements for its Markham, Ontario facility. 

The first deal will see the company pay C$1 million by issuing nearly 2 million shares of stock at a price of C$0.51 per share. The seller of the equipment is CMAX Technologies Inc, a related party of which Canntab CFO Richard Goldstein is the sole director and officer.

A deposit of 200,000 shares will be paid to CMAX within two weeks of the purchase agreement being executed. 

READ: Canntab Therapeutics announces the appointment of Larry Latowsky as its CEO with immediate effect

Additionally, the company has agreed to purchase $300,000 in cannabis processing equipment from Pharmagenerics Solutions Inc, which it will pay for by issuing 588,235 shares at the same C$0.51 price. 

Canntab is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. It holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

The company is also in the process of establishing a CBD manufacturing and distribution business in the US, through its wholly owned American subsidiary.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Canntab Therapeutics Ltd

Price: 0.96 CAD

Market: CSE
Market Cap: $34.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...


Canntab Therapeutics granted patent for their hard pill proprietary...

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the company, which has filed over a dozen patents, has been granted their second in relation to its proprietary cannabidiol formulations around the hard pill format. Goldstein...

on 02/01/2021

2 min read